Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro,
Which Received FDA Approval Late Last Year for the Treatment of
Hyperphosphatemia in Dialysis
Interest in GCS-100, Velcalcetide, ST-10, GSK-1278863A and Rayaldee Ranges
from Moderate to High, According to Findings from Decision Resources Group
BURLINGTON, Mass., July 10, 2014
BURLINGTON, Mass., July 10, 2014 /PRNewswire/ -- Decision Resources Group
finds that over half of surveyed nephrologists report awareness of the U.S.
Food and Drug Administration's (FDA) approval of Vifor Fresenius Medical Care
Renal Pharma's new phosphate binder Velphoro, which was approved by the FDA in
November 2013 for the treatment of hyperphosphatemia in chronic kidney disease
(CKD) patients on dialysis.
Decision Resources Group Logo.
Other key findings from the report entitled TreatmentTrends: Nephrology (US)
oBundling: Based on mean ratings, surveyed nephrologists are under the most
pressure from their dialysis unit to restrict measurement of nonessential
labs, to use lower doses of erythropoiesis-stimulating agents (ESAs) and
to have more stringent hemoglobin targets resulting in less ESA use.
Surveyed nephrologists believe that the delay of inclusion of oral
dialysis drugs into the end-stage renal disease payment bundle will
similarly impact future use of phosphate binders, oral iron and Amgen's
oIV Iron patient share in hemodialysis (HD): American Regent/Fresenius
Medical Care's Venofer has significantly declined in reported HD patient
share compared with this time period last year.
oNephrologists' perceptions of late-stage compounds in clinical
development: The report discusses aided familiarity, interest and
percentage of patients as likely candidates for 12 renal products in
development after review of product profiles. New product profiles added
to this quarter's report, include:
oLaJolla Pharmaceutical's GCS-100: Nearly half of nephrologists report
high interest in the product, which was higher than all other renal
anemia and bone mineral metabolism products in late-stage development
covered in this study.
oGSK's GSK-1278863A: Nearly one-third of nephrologists report high
interest in this oral renal anemia product.
oShield Therapeutics' ST-10: Nearly a third of nephrologists report
high interest in this oral ferric iron therapy.
oAmgen's Velcalcetide: Should this intravenous therapy for secondary
hyperparathyroidism (SHPT) receive FDA approval, nephrologists expect
significantly higher usage in the dialysis versus the CKD
non-dialysis (ND) setting.
oOPKO Health's Rayaldee: While familiarity is low, over 40 percent of
nephrologists report high interest in this oral Vitamin D therapy
used to treat SHPT being tested in CKD stage 3 and stage 4 patients,
after review of a product profile.
Comments from Decision Resources Group Director Rob Dubman:
o"Physicians are recalling lower number of pills as one of Velphoro's
primary messages from sales representatives. Not surprisingly, we have
found that in this and other studies that delivery attributes are not as
important compared with efficacy and safety attributes."
A special report that is expected to publish later this month entitled The
Impact of New Iron-Based Phosphate Binders on the Hyperphosphatemia Market
will also help manufacturers understand why and how Velphoro and Keryx
Pharmaceutical's Zerenex will be used, if Zerenex receives FDA approval later
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and
insights on critical issues within the healthcare industry. Clients rely on
this analysis and data to make informed decisions. Find out more at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO
SOURCE Decision Resources Group
Press spacebar to pause and continue. Press esc to stop.